Health Condition 1: E663- Overweight Health Condition 2: D510- Vitamin B12 deficiency anemia dueto intrinsic factor deficiency
Conditions
Interventions
Intervention1: Stable isotope labelled
cyanocobalamin: Stable Isotopically labelled
13C-cyanocobalamin (2.0 ug)
dose will be orally administered
on the study day to all study participants.
Control Int
Sponsors
Department of Biotechnology Government of India India Alliance
Eligibility
Inclusion criteria
Inclusion criteria: Subjects for pernicious anemia as characterized by peripheral blood smear. For overweight group BMI range from 25.0 to 30 Kg/m2
Exclusion criteria
Exclusion criteria: History of acute illness or surgeries in the past 3 months, on medication that can induce transient hyperglycemia, other endocrinological disorders that are known to affect glycemic status.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Vitamin B12 bioavailability in pernicious anemia 2. To assess the effect of metformin on B12 bioavailability in overweight participantsTimepoint: Among three overweight groups, except control group, all other participants will receive either 500 or 1000 mg of metformin for 3 days (dose once a day) and on Day-4 B12 bioavailability measurement will be performed with biospecimen collection over 10 hrs after the B12 dose administration For pernicious anemia subjects, one time measurement with biospecimen collection over 10 hrs after the B12 dose administration | — |
Secondary
| Measure | Time frame |
|---|---|
| To validate the functional biomarkers of B12 bioavailability in biospecimens.Timepoint: Baseline biospecimens | — |
Countries
India
Contacts
Public ContactDr Sarita Devi
St. Johns Research Institute
Outcome results
None listed